Health Care

Explore how SELLAS Life Sciences Group Inc. is advancing late‑stage oncology drugs, driving biopharma innovation and improving cancer treatment worldwide.

Explore Pfizer’s 2026 stock trend, market value, and R&D focus on precision oncology—see how the pharma giant’s strategy drives growth and investment.

Discover how Finland’s Revenio Group Oyj pioneers innovative tonometers, bone‑density tools, and digital health apps—boosting glaucoma care and expanding globally.

GSK PLC prepares to report Q4 earnings on Oct 28, with analysts projecting EPS of £0.505, while unveiling an $800 M U.S. expansion to boost vaccine capacity and create jobs.

NuWays AG sees Eckert & Ziegler SE as undervalued, bullish 12‑month rating, 21.50 EUR target, driven by its proprietary isotope supply chain and pharma strength.

Avantor Inc’s shaky stock, negative P/E, and 52‑week volatility highlight a key healthcare player at a crossroads – what strategies can revitalize its profitability?

Insilico Medicine Cayman Top leads medical AI in drug discovery, advancing therapy candidates and data‑driven diagnostics to boost patient outcomes.

Corrected insider stock acquisitions by Nakamoto Inc. directors: see updated holdings, share prices, and market cap on Nasdaq.

Discover how Certara’s biosimulation tech is speeding drug discovery, cutting costs, and shaping global healthcare—see its latest market outlook.

Gilead Sciences’ stock gains reflect investor confidence in its drug pipeline, driving a broader healthcare sector rebound in late October 2026.